Announcements Trials
Browse Landscape

Phase

Phase 1 10Phase NA 4Phase 2 4Phase 1/2 4Phase 4 2Phase 3 2Phase 2/3 1

Status

Suspended 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 2Thoracic 2Gastrointestinal 2Sarcoma 1Dermatologic 1

Conditions

Advanced Solid Tumor 13Leukemia, Myeloid, Acute 10Carcinoma, Non-Small-Cell Lung 7Advanced Solid Tumors 7Breast Neoplasms 6Solid Tumor 5Pancreatic Neoplasms 5Melanoma 5Triple Negative Breast Neoplasms 4Ovarian Neoplasms 4Neoplasms 4Neoplasm Metastasis 4Lymphoma, Non-Hodgkin 4Solid Tumors 3Recurrence 3Myelodysplastic Syndromes 3Lung Neoplasms 3Leukemia, Biphenotypic, Acute 3Esophageal Neoplasms 3Carcinoma, Hepatocellular 3Biliary Tract Neoplasms 3Advanced Malignant Solid Tumor 3Advanced Lung Cancer 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Prostatic Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2

Interventions

pembrolizumab 44Nivolumab 29Gemcitabine 28Paclitaxel 19Cisplatin 18Ipilimumab 15Carboplatin 14Cyclophosphamide 13Capecitabine 12Dexamethasone 10Bevacizumab 10cemiplimab 9Irinotecan 9Docetaxel 9Albumin-Bound Paclitaxel 9130-nm albumin-bound paclitaxel 9spartalizumab 8Pemetrexed 8Sorafenib 7Rituximab 7Cetuximab 7fludarabine 6Temozolomide 6Taxes 6Radiotherapy 6Leucovorin 6Fluorouracil 6Azacitidine 6Ascorbic Acid 6lenvatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms × Injections × Clear all
NCT04908111 2026-04-06

A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1

Cancer Research UK

Phase 1/2 Suspended
15 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Lung Neoplasms, Neoplasms, Neoplasms, Squamous Cell

NCT05516914 2026-04-01

A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors

Nanjing Leads Biolabs Co.,Ltd

Phase 1/2 Completed
98 enrolled
Tumor-Agnostic

Neoplasms

NCT07112222 2026-01-26

A Study of LM-350 in Subjects With Advanced Solid Tumours

LaNova Medicines Limited

Phase 1/2 Recruiting
80 enrolled
Tumor-Agnostic

Neoplasms

NCT05688280 2025-01-08

INJECTABL-1

Immunophotonics, Inc.

Phase 1/2 Active not recruiting
42 enrolled
DermatologicGastrointestinalSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡